Wedbush sees recent pullback in Immunome share price as buying opportunity

Wedbush continues to hold a positive opinion on Immunome and sees the recent pullback in share price as a buying opportunity for long-term investors. The firm notes that the company reported Q1 earnings, and recently closed the purchase of Ayala Pharmaceuticals’ small molecule gamma secretase inhibitors AL101 and AL102 on March 25, 2024. AL102 is currently in a fully enrolled Phase 3 trial – RINGSIDE – for the treatment of desmoid tumors. Enrollment was completed in February and Immunome plans to report topline data from part B of the study in the second half of 2025. In the meantime, the company will continue its efforts to support an NDA for AL102, including manufacturing and pharmacology work. Wedbush has an Outperform rating on the shares with a price target of $33.